These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38820506)

  • 1. Gut microbiome in the Graves' disease: Comparison before and after anti-thyroid drug treatment.
    Jeong C; Baek H; Bae J; Hwang N; Ha J; Cho YS; Lim DJ
    PLoS One; 2024; 19(5):e0300678. PubMed ID: 38820506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between gut microbiota and thyroidal function status in Chinese patients with Graves' disease.
    Chen J; Wang W; Guo Z; Huang S; Lei H; Zang P; Lu B; Shao J; Gu P
    J Endocrinol Invest; 2021 Sep; 44(9):1913-1926. PubMed ID: 33481211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease.
    Jiang W; Yu X; Kosik RO; Song Y; Qiao T; Tong J; Liu S; Fan S; Luo Q; Chai L; Lv Z; Li D
    Thyroid; 2021 May; 31(5):810-820. PubMed ID: 33234057
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hyperthyroidism with antithyroid drugs corrects mild neutropenia in Graves' disease.
    Aggarwal N; Tee SA; Saqib W; Fretwell T; Summerfield GP; Razvi S
    Clin Endocrinol (Oxf); 2016 Dec; 85(6):949-953. PubMed ID: 27291145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy.
    Shi TT; Xin Z; Hua L; Wang H; Zhao RX; Yang YL; Xie RR; Liu HY; Yang JK
    J Endocrinol Invest; 2021 Feb; 44(2):297-310. PubMed ID: 32449092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.
    Moshkelgosha S; Verhasselt HL; Masetti G; Covelli D; Biscarini F; Horstmann M; Daser A; Westendorf AM; Jesenek C; Philipp S; Diaz-Cano S; Banga JP; Michael D; Plummer S; Marchesi JR; Eckstein A; Ludgate M; Berchner-Pfannschmidt U;
    Microbiome; 2021 Feb; 9(1):45. PubMed ID: 33593429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
    Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
    Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
    Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
    Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy.
    Rotondi M; Cappelli C; Pirali B; Pirola I; Magri F; Fonte R; Castellano M; Rosei EA; Chiovato L
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3985-8. PubMed ID: 18664537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
    Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction for recurrence following antithyroid drug therapy for Graves' hyperthyroidism.
    Weng H; Tian WB; Xiao ZD; Xu L
    Arch Endocrinol Metab; 2023 May; 67(4):e000609. PubMed ID: 37252698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
    Choi YM; Kwak MK; Hong SM; Hong EG
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):268-274. PubMed ID: 31565879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction.
    Huang H; Shi Y; Liang B; Cai H; Cai Q; Lin R
    Clin Endocrinol (Oxf); 2018 Mar; 88(3):473-478. PubMed ID: 29288501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study.
    Song E; Kim M; Park S; Park MJ; Kim JA; Roh E; Yu JH; Kim NH; Seo JA; Kim SG; Kim NH; Choi KM; Baik SH; Yoo HJ
    Front Endocrinol (Lausanne); 2021; 12():761782. PubMed ID: 34690936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Graves' hyperthyroidism: present and future.
    Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?
    Park S; Song E; Oh HS; Kim M; Jeon MJ; Kim WG; Kim TY; Shong YK; Kim DM; Kim WB
    Endocrine; 2019 Aug; 65(2):348-356. PubMed ID: 31236779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of Gut Microbiota in Patients With Graves' Disease.
    Chang SC; Lin SF; Chen ST; Chang PY; Yeh YM; Lo FS; Lu JJ
    Front Cell Infect Microbiol; 2021; 11():663131. PubMed ID: 34026662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.